The tragedy of the anticommons occurs when rational individuals (acting separately) collectively waste a given resource by under-utilizing it. This is the canonical justification for the takings clause in the US Constitution and eminent domain generally. This happens when too many individuals have rights of exclusion (such as property rights) in a scarce resource. This situation (the "anticommons") is contrasted with a commons, where many individuals have privileges of use (or the right not to be excluded) in a certain resource. The tragedy of the commons is that rational individuals, acting separately, may collectively over-utilize a scarce resource.
The term "tragedy of the anticommons" was originally coined by Harvard Law professor Frank Michelman and popularized in 1998 by Michael Heller, a law professor at Columbia Law School. Michelman and Heller pointed to biomedical research as one of the key areas where competing patent rights actually prevent useful and affordable products from reaching the marketplace. The countereffect of the tragedy of the anticommons, the increased usefulness of a resource as the result of many individuals using it, has been dubbed the comedy of the commons by Lawrence Lessing. It is related to the concepts of network effects and non-rivalrous goods.
After the fall of Communism, it was noted that in many Eastern European cities there were a lot of open air kiosks, but also a lot of empty stores. Upon investigation, it was found that because many different agencies and private parties had rights over the use of store space, it was difficult or even impossible for a startup retailer to successfully negotiate for the use of that space. Even though all the persons with ownership rights were losing money with the empty stores, and stores were in great demand, their competing interests got in the way of the effective utilization of space.
Patents often provide examples of the tragedy of the anticommons because a patent owner has exclusive rights over the use of the patented technology. If the creation of a certain product involves the use of many techniques and components patented by different people or different companies, then it can be very difficult to negotiate effectively with all the patent holders at once, and the result may be that one has to pay so many license fees that it becomes too expensive to create the desired product. In other words, a product that is in great demand may not be produced because costs associated with patents are too high. Different industries have different ways to deal with this problem.
In a few industries (e.g., pharmaceuticals) a single patent is all that is required to produce a marketable product that can be protected from competitors in the marketplace. If it becomes necessary for someone other than the patent holder to produce the product to meet demand, only negotiation with a single owner is necessary, and a license can usually be worked out. For example, if a patented anti-viral drug is needed in far larger quantities to quell an epidemic, the government can usually enforce a license agreement with a single patent holder in order to meet society's needs.
However, in most industries, a manufacturer will need to negotiate to use several patents in order to legally create a product. For example, a DVD player contains about a dozen devices that are patented by different companies. A single microchip can contain over 5,000 different patents. As such, no-one could create a DVD player or a microchip unless every one of the patent holders agreed to license their patent to other manufacturers. In many industries, patent holders either agree to cross-license their patents (i.e., you can use ours if we can use yours) or work out a common licensing agreement that make the product affordable. This generally means that for DVD players, computer components and other consumer electronics, the cost of licensing the patents is rarely much more than the manufacturing costs. For example, the license costs for the patents of a DVD player are about $20.00 (U.S.) for the cheapest models.
Due to the ease of patenting biological discoveries, it is likely that anyone working in biomedical research will have to use several patented procedures in order to create a marketable product. However, since those patents are short lived and only a few patents result in a marketable product, those developing new treatments or processes often find that negotiating a licensing agreement with the patent holders is prohibitively expensive and will result in the product being unmarketable. In fact, a patent holder can often say that mere research is an infringing use, and demand a license fee even though the chance of developing a marketable product is slim.
However, even one questionable patent can make marketing a product legally impossible. The recent dispute between Research In Motion and NTP, Inc. is over a single disputed wireless e-mail patent that is a key element of the BlackBerry. This was settled by the parties and did not result in an injunction that would have prevented the sale of the BlackBerry in the United States.
This article is licensed under the GNU Free Documentation License.
It uses material from the
"Tragedy of the anticommons".
Home Page • arts • business • computers • games • health • hospitals • home • kids & teens • news • physicians • recreation• reference • regional • science • shopping • society • sports • world